Tildacerfont

Generic Name: Tildacerfont

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₆ClN_₅OS

CAS Number: 1014983-00-6

Unique Ingredient Identifier: 09QCEV5481

Background: Tildacerfont is a corticotropin-releasing factor receptor-1 antagonist containing an unfused thiazole ring

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens

Phase 2

Completed

Conditions: Polycystic Ovary Syndrome

Interventions: Drug: Placebo
Drug: Tildacerfont

First Posted Date: 2022-05-11

Last Posted Date: 2023-09-28

Lead Sponsor: Spruce Biosciences

Target Recruit Count: 27

Registration Number: NCT05370521

Locations: 🇺🇸
Spruce Study Site, Morgantown, West Virginia, United States

A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children with CAH

Phase 2

Recruiting

Conditions: 21-OHD
Congenital Adrenal Hyperplasia

Interventions: Drug: Tildacerfont

First Posted Date: 2021-11-22

Last Posted Date: 2024-12-03

Lead Sponsor: Spruce Biosciences

Target Recruit Count: 70

Registration Number: NCT05128942

Locations: 🇺🇸
Spruce Study Site, Richmond, Virginia, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy